

Special Issue

Targeted Radionuclide Therapy: Theranostic Applications and Advances in Personalized Therapy

Message from the Guest Editors

Targeted radionuclide therapy (TRT) is a radiation therapy modality consisting of systemic delivery of radioactive atoms to induce DNA damage in tumor cells. TRT agents target specific receptors or molecular cues overexpressed in tumor cells or the microenvironment. Recent developments in understanding of radionuclide chemistry and physical characteristics of radionuclides, as well as biological insights on appropriate and specific molecular targets, have promoted increased use of TRT, especially within a theranostic approach. Herein, we aim at highlighting the most recent applications of targeted radionuclide therapy through the use of different ligands and tumor targeting agents, in combination with diagnostic approaches or other cancer therapies for personalized cancer treatment.

Guest Editors

Dr. Carolina de Aguiar Ferreira

Department of Medical Physics, University of Wisconsin-Madison, Madison, WI 53705, USA

Dr. Leonardo Lima Fuscaldi

Department of Physiological Sciences, Santa Casa de Sao Paulo School of Medical Sciences, Sao Paulo, SP 01221-020, Brazil

Deadline for manuscript submissions

closed (30 November 2022)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/117163

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).